Fig. 3

The Menin-MLL1 inhibitor induced differentiation and loss of CD34 + /CD38 − cells in patient-derived MLL1-r + AML cells (AML#8531, AML676, and NCCHD010) in vitro. Patient-derived primary AML cells (MLL1-r AML#8531, NCCHD010, AML676) were treated for 7 days with DMSO, DS-1594a·succinate, or Ara-C at the indicated concentrations. A FCM analysis with anti-human CD34/CD38 antibodies. The bars represent the mean ± SD; n = 3. B FCM analysis with anti-human CD11b. The bars represent the mean ± SD; n = 3. C RT‒qPCR to detect the expression levels of MEIS1 and HOXA9 (mean ± SD; n = 3) normalized to that of ACTB